Universal Vision Biotechnology Co., Ltd.
Research Universal Vision Biotechnology Co., Ltd. (3218.TWO) on Bullrun: market cap TWD 11.23B, P/E 9.8, dividend yield 6.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3218.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryMedical Care Facilities
- CurrencyTWD
- Market capTWD 11.23B
- P/E9.8
- Dividend yield6.2%
- Financial periodQ2 2026
- RevenueTWD 1.13B
- Net incomeTWD 226.46M
- Free cash flowTWD 307.45M
- Gross margin57.7%
Valuation Snapshot
latest market cap is TWD 11.23B; P/E is 9.8; dividend yield is 6.2%.
Peer valuation comparison
Latest P/E is 9.81x versus a Healthcare sector median of 21.8x (55.0% below).
Latest dividend yield is 6.15% versus a Healthcare sector median of 2.4% (156.3% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 11.23B | 9.8 | 5.9% | 7.75 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 7.75 TWD, yield 6.2%.
About Universal Vision Biotechnology Co., Ltd.
Universal Vision Biotechnology Co., Ltd., a biotech company, provides vision care services in Taiwan and China. The company offers various glasses and lenses for vision correction, contact lens solutions, and related eye care products; equipment rental and technical services for laser vision correction instruments; and technology and services for cataract and dry eye examination and treatment instruments.
ETFs that hold Universal Vision Biotechnology Co., Ltd.
US-listed ETFs
Universal Vision Biotechnology Co., Ltd. is held by 16 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Universal Vision Biotechnology Co., Ltd.'s market cap?
Universal Vision Biotechnology Co., Ltd.'s market capitalization is TWD 11.23B.
What is Universal Vision Biotechnology Co., Ltd.'s P/E ratio?
Universal Vision Biotechnology Co., Ltd.'s price-to-earnings (P/E) ratio is 9.8.
Does Universal Vision Biotechnology Co., Ltd. pay a dividend?
Universal Vision Biotechnology Co., Ltd. has a dividend yield of 6.2%.
What does Universal Vision Biotechnology Co., Ltd. do?
Universal Vision Biotechnology Co., Ltd., a biotech company, provides vision care services in Taiwan and China. The company offers various glasses and lenses for vision correction, contact lens solutions, and related eye care products; equipment rental and technical services for laser vision correction instruments; and technology and services for cataract and dry eye examination and treatment instruments.